Cangene’s Accretropin “Approvable” Pending Resolution Of Manufacturing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian biopharmaceutical firm expects to quickly resolve FDA’s manufacturing concerns for the human growth hormone.